{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:03:14Z","timestamp":1790733794579,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.msard.2021.102838","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T04:56:23Z","timestamp":1612932983000},"page":"102838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients"],"prefix":"10.1016","volume":"50","author":[{"given":"Zo\u00e9 L.E.","family":"van Kempen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannis A.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Hoogervorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7196-9826","authenticated-orcid":false,"given":"Alyssa","family":"Toorop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machteld I.","family":"Bosscha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Frequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninette ten","family":"Dam-van Loon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike P.","family":"Wattjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Murk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M.J.","family":"Uitdehaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102838_bib0001","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1212\/WNL.0000000000002302","article-title":"Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab","volume":"86","author":"Bourre","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102838_bib0002","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1212\/01.wnl.0000439052.05262.1d","article-title":"Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab","volume":"81","author":"Bourre","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102838_bib0003","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/eye.2011.338","article-title":"Acute retinal necrosis in the United Kingdom: results of a prospective surveillance study","volume":"26","author":"Cochrane","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.msard.2021.102838_bib0004","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/cid\/cit376","article-title":"Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients","volume":"57","author":"Fine","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2021.102838_bib0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-510X(98)00153-1","article-title":"The value of cerebrospinal fluid antiviral antibody in the diagnosis of neurologic disease produced by varicella zoster virus","volume":"159","author":"Gilden","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.102838_bib0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.msard.2016.10.002","article-title":"Extratemporal herpes encephalitis during natalizumab treatment: a case report","volume":"10","author":"Haggiag","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102838_bib0007","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-11-19","article-title":"Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab","volume":"11","author":"Kobeleva","year":"2014","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.102838_bib0008","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1352458517711569","article-title":"Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab","volume":"24","author":"Mulero","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102838_bib0009","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1136\/bjo.2007.114884","article-title":"Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK","volume":"91","author":"Muthiah","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.msard.2021.102838_bib0010","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1212\/NXI.0000000000000475","article-title":"VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab","volume":"5","author":"Pawlitzki","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.102838_bib0011","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/ICB.0000000000000136","article-title":"Acute retinal necrosis and immune reconstitution inflammatory syndrome in a natalizumab-treated patient with multiple sclerosis","volume":"9","author":"Saraiva","year":"2015","journal-title":"Retin Cases Brief Rep."},{"key":"10.1016\/j.msard.2021.102838_bib0012","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12348-016-0095-y","article-title":"Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab","volume":"6","author":"Sood","year":"2016","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"10.1016\/j.msard.2021.102838_bib0013","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1212\/WNL.0000000000001611","article-title":"Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab","volume":"84","author":"Van Tassel","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:54:19Z","timestamp":1761900859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821001048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":13,"alternative-id":["S2211034821001048"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102838","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102838"}}